Historical zts News Stories

Zoetis Faces Legal Scrutiny Amid Stock Volatility and Guidance Revisions

Zoetis under investigation following stock plunge and guidance cut.

Zoetis Reports Q1 2026 Results Amidst Strategic Investments and Pipeline Expansion

Zoetis announces Q1 2026 financials, strategic investments, and pipeline growth.

Zoetis Q1 Weakness Trims Guidance, Splits Analysts

Zoetis reported softer-than-expected Q1 results with adjusted EPS of $1.53 and revenue of roughly $2.3B, prompting a narrowed full-year outlook. U.S. companion-animal softness pressured diagnostics and genetic-testing momentum. Analyst reactions diverged—UBS trimmed to Neutral with a $130 target while Citi initiated Buy at $145—creating near-term volatility for ZTS stock.

Zoetis Plunge: Q1 Miss, Guidance Cut Shocks ZTS

Zoetis shares tumbled after a disappointing Q1 report and reduced 2026 outlook, driven by an 11% drop in U.S. companion-animal sales. International and livestock segments showed strength, while peers in diagnostics outperformed—raising questions about near-term recovery and the impact of Zoetis’s Neogen acquisition.

Zoetis OptiCell CHCM Upgrade Fuels Citi Buy $145Q2

Zoetis strengthened its point-of-care diagnostics with a CHCM upgrade to Vetscan OptiCell and received a Citi Buy initiation at $145, positioning diagnostics as a key near-term catalyst ahead of Q2 earnings.

Zoetis Boosts Genomics: Neogen Deal & BRD Rollout.

Zoetis recently completed a strategic acquisition of Neogen’s animal genomics business and has commercialized BRD genetic prediction metrics. With no fresh announcements in the past week, investor attention turns to integration, early adoption rates, and upcoming commercialization milestones that will influence ZTS performance.

Zoetis ZTS: BRD Genetics Boost Amid Guidance Trim.

Zoetis reported Q4 results and conservative 2026 guidance while launching commercial BRD genetic predictions for beef herds. The earnings and the new INHERIT BRD tools together reshape near-term sentiment but reinforce Zoetis's long-term strength in diagnostics and precision genetics.

Zoetis to Buy Neogen Genomics: ZTS Near-Term Up Q1

Zoetis announced a $160M purchase of Neogen’s animal genomics unit, expanding its precision animal health capabilities. The acquisition and a sharp spike in trading volume drove investor attention to ZTS; price moves were muted amid integration uncertainty. Key investor considerations include integration costs, timing for revenue synergy, and the opportunity to scale genotyping services across livestock and companion-animal customers.

Zoetis Q4 Beat, OA Antibodies and Vaccine Gains Q1

Zoetis reported stronger-than-expected Q4 2025 results and issued upbeat 2026 guidance, while regulatory approvals for long‑acting osteoarthritis antibodies and several animal vaccines added concrete near-term revenue drivers—developments that materially affect ZTS stock outlook.

Zoetis ZTS: $1.75B Notes AI Diagnostics Push

Zoetis (ZTS) reported modest Q4 results and set measured 2026 guidance while launching a $1.75B convertible note offering to support buybacks and strategic investments. The company is increasing its dividend and accelerating AI-enabled veterinary diagnostics and a deep therapeutic pipeline—factors that collectively shape near-term capital structure and longer-term growth prospects.

Zoetis ZTS: Durham Diagnostics Lab, AI Power Gains

Zoetis (ZTS) recently opened a major diagnostics and biodevices R&D facility in Durham and highlighted AI-driven discovery and a deep pipeline during an innovation webcast. These concrete investments strengthen Zoetis’s diagnostics capabilities and could accelerate product development timelines—important signals for investors following ZTS.